v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Segment Reporting Information [Line Items]    
Total revenue $ 1,533 $ 1,481
Total research and development 11,255 9,529
General and administrative 8,117 6,453
Total operating expenses 19,372 15,982
Loss from operations (17,839) (14,501)
Other Nonoperating Income (Expense) [Abstract]    
Interest income 132 343
Interest expense (1,320) (1,257)
Other (expense) income, net (150) 65
Total other (expense) income (1,338) (849)
Net loss (19,177) (15,350)
Collaborative arrangement revenue    
Segment Reporting Information [Line Items]    
Total revenue 1,533 1,481
Total research and development 800 800
Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development personnel costs 5,509 4,020
Facilities and other support costs 833 966
Other 742 1,070
Total research and development 11,255 9,529
General and administrative 8,117 6,453
Total operating expenses 19,372 15,982
Loss from operations (17,839) (14,501)
Other Nonoperating Income (Expense) [Abstract]    
Interest income 132 343
Interest expense (1,320) (1,257)
Other (expense) income, net (150) 65
Total other (expense) income (1,338) (849)
Net loss (19,177) (15,350)
Reportable Segment | OCU400    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 1,299 1,835
Reportable Segment | OCU410 and OCU410ST    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 2,625 1,190
Reportable Segment | NeoCart    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 12 (3)
Reportable Segment | COVAXIN    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 7 5
Reportable Segment | Inhaled mucosal vaccine platform    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 30 197
Reportable Segment | OCU200    
Segment Reporting Information [Line Items]    
Research and Development Expense (Excluding Acquired in Process Cost) 198 249
Reportable Segment | Collaborative arrangement revenue    
Segment Reporting Information [Line Items]    
Total revenue $ 1,533 $ 1,481